{"filings":[{"id":90783,"accession_number":"0001628280-26-032987","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rockwell Medical receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice issued May 8, 2026 for failing to meet $1.00 minimum bid price over 30 consecutive business days.","Company has 180 calendar days (until November 4, 2026) to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days.","Reverse stock split proposal included in 2026 Annual Meeting proxy to address the deficiency.","No immediate impact on listing; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90782,"accession_number":"0001628280-26-031680","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical makes corporate presentation available; no specifics extractable from filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Rockwell Medical made an updated corporate presentation available on May 7, 2026.","The exhibit text (Exhibit 99.1) was not provided in full for analysis.","No quantitative guidance, earnings, or other material metrics are available from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90781,"accession_number":"0001628280-26-031629","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 net sales $17.3M (-8% YoY); guides FY26 gross margin 18-22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $17.3M, down 8% from $18.9M; net loss $1.6M vs $1.5M in prior year.","Gross margin improved to 17% from 16%; gross profit $2.9M flat YoY.","FY26 guidance: net sales $70-75M, gross margin 18-22%, Adj. EBITDA $1-2M, positive op. cash flow.","Operational changes expected to generate >$3M annualized additional gross profit.","Cash $23.9M at March 31; final $0.5M Evoqua earnout payment made in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":17336000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100574,"accession_number":"0001628280-26-021195","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical files updated corporate presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated March 26, 2026 made available under Item 7.01.","No financial guidance, M&A, leadership changes, or other material events disclosed.","Presentation content is consistent with prior public disclosures; no new metrics or targets provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100573,"accession_number":"0001628280-26-021176","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.","Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.","Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.","Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.","2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100572,"accession_number":"0001628280-26-002478","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).","Gross margin improved to ~22% in Q4, up from 14% in Q3 2025.","Q4 cash flow from operations ~$2.3M, second cash-positive quarter; cash & equivalents ~$25M at year-end.","CEO highlighted revenue growth, increased profitability, and portfolio diversification as 2026 focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":69258000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100571,"accession_number":"0001628280-26-000221","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rockwell Medical extends DaVita supply agreement to Dec 2026 with price hike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment extends Products Purchase Agreement through Dec 31, 2026.","Amendment provides for a price increase on products sold during the extension term.","Amendment effective December 23, 2025; extension adds one year to original term.","Original agreement with DaVita dated September 18, 2023, previously amended March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116898,"accession_number":"0001104659-25-113452","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rockwell Medical director resigns; Joseph H. Dawson appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Andrea Heslin Smiley resigned Nov 17, 2025; resignation not due to disagreement.","Joseph H. Dawson appointed as Class II director effective Nov 17, 2025, to serve until 2026 annual meeting.","Dawson, 60, former President North America of Nipro Medical (2013-2025), also joined Nominating Committee.","Director compensation: $45k cash retainer + $5k committee fee (pro-rated), plus option for 25k shares and 25k RSUs vesting Nov 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116897,"accession_number":"0001628280-25-051311","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made available an updated corporate presentation on November 12, 2025.","Presentation covers corporate strategy, business overview, and market positioning.","No earnings, financial guidance, or material operational metrics were included.","Investors are directed to the company's website for the full presentation.","Filing does not contain any new contracts, partnerships, or financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116896,"accession_number":"0001628280-25-051267","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.","Net loss of $1.8M compared to net income of $1.7M in Q3 2024; Adjusted EBITDA virtually breakeven at $50k.","Gross margin contracted to 14% (18% excluding restructuring) from 22% a year ago.","Cash increased to $23.7M from $18.4M at June 30, driven by ATM stock issuance.","Reaffirms 2025 guidance: net sales $65-70M, gross margin 16-18%, Adjusted EBITDA ($0.5M)-$0.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":50912000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133333,"accession_number":"0001104659-25-094524","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rockwell Medical appoints Heather Hunter as SVP & COO effective Sept 23, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Hunter appointed SVP & COO effective Sept 23, 2025; previously SVP & Chief Corporate Affairs Officer since Aug 2022.","Annual base salary $323,574; target bonus 45% of base salary; eligible for long-term incentive grants.","Initial time-based option grant of 60,000 shares, vesting over 4 years from Aug 29, 2022.","Severance upon termination without cause/good reason: 12 months base salary plus COBRA reimbursement.","Change of control severance: lump sum 1x base salary plus prorated target bonus; full acceleration of time-based awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133332,"accession_number":"0001041024-25-000009","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.","Net loss $1.5M vs net income $0.3M in Q2 2024; Adjusted EBITDA -$0.2M vs $1.4M year ago.","Cash & investments increased to $18.4M, supported by $1.8M operating cash flow.","Reaffirmed 2025 guidance: net sales $65-70M, gross margin 16-18%, Adj EBITDA -$0.5M to $0.5M.","Secured multi-year supply agreements with Innovative Renal Care (3-yr) and other providers; >80% customers under long-term contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":34985000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149998,"accession_number":"0001104659-25-050997","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical shareholders elect directors, approve advisory say-on-pay and 5M share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors John G. Cooper and Allen Nissenson, MD re-elected with 14.3M and 14.4M votes for, respectively.","Advisory vote on executive compensation passed with 13.3M for, 1.1M against, 0.55M abstain, and 8.4M broker non-votes.","Ratification of EisnerAmper LLP as auditor for 2025 approved: 21.8M for, 0.36M against, 1.2M abstain.","Amendment to 2018 Long Term Incentive Plan increasing shares by 5,000,000 approved: 12.9M for, 2.0M against, 0.05M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149997,"accession_number":"0001628280-25-024444","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation made available on May 12, 2025 under Item 7.01.","Specific content and figures from the presentation are not provided in the filing.","No new financial guidance, material events, or operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149996,"accession_number":"0001104659-25-046957","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 net sales $18.9M (-17% YoY); net loss improves to $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales fell 17% to $18.9M, driven by largest customer transitioning to another supplier.","Received a one-time non-refundable payment of $0.9M from that customer to ensure supply continuity.","Net loss improved 12% to $1.5M ($0.04 loss per share) vs $1.7M in Q1 2024.","Adjusted EBITDA was -$0.4M; cash and investments $17.3M, down $4.3M from year-end 2024.","Reaffirmed 2025 guidance: net sales $65M-$70M, gross margin 16%-18%, adjusted EBITDA -$0.5M to $0.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":18914000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169008,"accession_number":"0001628280-25-014017","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation; no specific new details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 7.01 Regulation FD disclosure with corporate presentation dated March 20, 2025.","No material financial or operational data from the presentation is included in the 8-K or summary.","Presentation is furnished, not filed, and not incorporated by reference into SEC filings.","Investors should refer to the full presentation for any potential updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169007,"accession_number":"0001104659-25-025782","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Reports Record Net Sales and First Full-Year Adjusted EBITDA Profitability in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales of $101.5M in 2024, a 21% increase over 2023.","Record gross profit of $17.5M in 2024, a 101% increase over 2023.","Full-year adjusted EBITDA reached $5.2M, first time profitable on that basis.","Net loss improved 94% to $0.5M in 2024 from $8.4M in 2023.","Largest customer transitioning away; expects ~$34M revenue loss in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186092,"accession_number":"0001104659-24-128064","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rockwell Medical appoints Jesse Neri as CFO effective December 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jesse Neri, previously SVP Finance since Oct 2023, becomes CFO and Principal Financial Officer.","Annual base salary of $300,000; target bonus 45% of base salary.","Received initial option grant of 75,000 shares vesting over 4 years.","Neri had served as SVP Finance and principal accounting officer since Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186091,"accession_number":"0001104659-24-117447","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rockwell Medical files prospectus supplement for up to $25M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new S-3 shelf registration on Oct 8, effective Oct 21, replacing expiring prior shelf.","Prospectus supplement filed Nov 13 covers up to $25M of common stock under Cantor Fitzgerald sales agreement.","Sales agreement dated April 8, 2022; this supplement updates the at-the-market offering capacity.","Legal opinion from Gibson Dunn on securities legality attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186090,"accession_number":"0001628280-24-046835","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical provides updated corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated corporate presentation as Exhibit 99.1 to Form 8-K on November 12, 2024.","Presentation content is not provided in the filing; no new financial or operational figures are available.","Filing is under Regulation FD; presentation is furnished, not filed, and not incorporated by reference.","Investors should refer to the actual presentation for any updates on strategy or performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186089,"accession_number":"0001628280-24-046792","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.","Net income $1.7M vs loss $1.9M in Q3 2023; adjusted EBITDA $2.8M vs negative $1.2M.","Cash from operations $4.3M; cash and equivalents $18.3M, up from $11.9M at June 30.","2024 guidance raised: net sales $98-101M, gross profit $15-17M, adjusted EBITDA $4-5M.","Largest customer extended through Dec 2025 but expects volume decline of $31-38M in 2025; company aims to offset with new contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":76824000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202707,"accession_number":"0001628280-24-036211","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical issues updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available on August 8, 2024 under Item 7.01 Regulation FD.","No financial or operational data from the presentation included in the 8-K filing.","Investors should refer to the presentation itself for any updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202706,"accession_number":"0001628280-24-035830","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.","Net income $0.3M vs net loss of $3.3M in Q2 2023; adjusted EBITDA $1.5M vs negative $2.3M.","Generated $1.4M in cash flow from operations; cash and equivalents rose to $11.9M from $8.6M.","FY 2024 net product sales guidance raised to $95M–$98M (from $90M–$94M) and Adjusted EBITDA to $0.75M–$1.5M.","Promoted Tim Chole to Chief Commercial Officer; amended Evoqua asset purchase agreement for extended payment terms."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":48508000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202705,"accession_number":"0001104659-24-079679","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Rockwell Medical amends asset purchase deal with Evoqua; affirms 2024 gross margin guidance of 14-16%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces First Deferred Payment by $322,260 to $2,177,740, payable in four quarterly installments through April 2025.","Second Deferred Payment of $2.5M payable in four quarterly installments from July 2025 to April 2026.","CEO reaffirmed 2024 non-GAAP gross margin guidance of 14-16% at HC Wainwright conference, correcting a prior misstatement of 13-15% that referred to gross profit dollars.","Amendment clarifies undeliverable equipment is excluded from acquired assets and includes a release of claims related to expired inventory disposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218866,"accession_number":"0001628280-24-025011","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical shareholders elect directors, approve compensation, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Radie and Mark Strobeck elected Class III directors with ~11.5M votes each; broker non-votes ~8.1M.","Advisory say-on-pay resolution approved: 11,126,598 for, 522,245 against, 83,718 abstain.","EisnerAmper LLP ratified as independent auditor for 2024 with 19,446,483 for, 210,240 against, 193,112 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218865,"accession_number":"0001628280-24-023287","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation; details not disclosed in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Item 7.01 disclosure: company made available an updated corporate presentation on May 14, 2024.","Presentation furnished as Exhibit 99.1; no specific financial or operational data extracted.","Form 8-K states information is furnished, not filed, and not incorporated by reference.","No new material events or changes are explicitly described beyond the availability of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218864,"accession_number":"0001628280-24-023035","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).","Net loss improved to $1.7M from $1.8M YoY; adjusted EBITDA ($0.5M) vs ($1.0M).","Raised FY2024 guidance: net sales $90-94M (prev $84-88M); gross profit $13-15M; adjusted EBITDA $0.5-1.0M.","Amended Innovatus loan: rate reduced, maturity extended to Jan 2029; interest-only through Sep 2026.","New distribution deals with BioNuclear and AMI expected ~$1M annual revenue; new supply agreement with large Mountain West health system."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":22676000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238768,"accession_number":"0001628280-24-012367","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation on March 21, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1; specific content (strategy, financials, pipeline) not reproduced in 8-K text.","Investors should review the presentation directly for any material updates.","No new financial metrics, guidance, or operational changes disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238767,"accession_number":"0001104659-24-036897","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.","Full-year 2023 net sales $83.6M (+15% YoY); gross profit $8.7M (+114% YoY); net loss improved 55% to ($8.4M).","2024 guidance: net product sales $84-88M (5-10% growth), gross margin 14-16%, and full-year adjusted EBITDA $0-0.5M.","Amended Innovatus loan: interest rate reduced, maturity extended to Jan 2029; interest-only payments for 30-36 months.","Acquired Evoqua hemodialysis concentrates assets in July 2023; became leading US liquid bicarbonate supplier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}